Feasibility of Calcium Alginate Microcapsules of Oral Sustained Release Suspensions of Propranolol Hydrochloride Using Ion Exchange Resinates Microcapsules of sustained release propranolol suspensions
Iranian Journal of Pharmaceutical Sciences,
Vol. 7 No. 4 (2011),
1 October 2011
,
Page 231-236
https://doi.org/10.22037/ijps.v7.41294
Abstract
An oral suspension could a suitable dosage form for the geriatric patients. The calcium alginate coated ion exchange resinate of propranolol hydrochloride were prepared using Amberlite IR-120 by solvent evaporation. Microcapsules of propranolol hydrochloride resinate were prepared by solvent evaporation technique, the suspensions were prepared by using deionised water as the vehicle. Methyl cellulose and Tween 80 were used as suspending agents in four different concentrations: 0.5, 1, 1.5 and 2%. The suspensions were evaluated for physical
stability, redispersibilty and in vitro release patterns. Microcapsules of propranolol hydrochloride corresponding to drug polymer ratios of 1:1.0, 1:1.5, 1:2.0, 1:2.5 and 1:3.0 were evaluated for physical stability, percentage yield, particle size, and in vitro drug release profile. The drug loading capacity of ion exchange resine was found to be 41% (w/v). The suspensions were prepared with 1.5% Tween 80 had good physical stability and redispersibilty and in vitro release patterns, and were also suitable for sustained release formulation. Therefore, calcium alginate coated propranolol hydrochloride formulation as oral sustained suspension is an effective system, which can be suitable dosage form for geriatric use.
- Amberlite IR120;
- Calcium alginate;
- Microcapsules;
- Propranolol.
How to Cite
References
[2] Smith HA, Evanson RV, Sperandio G.J. The development of a liquid antihistaminic preparation with sustained release properties. J Am Pharm Assoc Sci Ed 1960; 49: 94-7
[3] Moldenhauer MG, Narin JG. Formulation parameters affecting the preparation and properties of microencapsulated ion-exchange resins containing theophylline. J Pharm Sci 1990; 79:659-66.
[4] Riens EJ. Drug Design Vol IV, 1973; Academic press, New York, p, 47.
[5] Unzel K. Die, “Zerfallsprufung” einzeldosierter oraler Arzneiformen mit verlangerter Wirkung in vitro Arch Pharma 1960; 293: 766-85.
[6] Artin A. Physical Pharmacy, 4th edn, B I Wavely, New Delhi 1993; pp. 480-1.
[7] Howard SA, Mauger JW, Hsieh JW, Amin K. Suspending agent effects on steroid suspension dissolution profiles. J Pharmascience 1979; 68;1475-9.
[8] Higuchi J. Mechanism of sustained-action Medication. Theoretical analysis of rate release of solid drugs disperesed in solid matrices. J Pharm Sci 1963; 52:1145-9.
[9] The united states pharmacopoeia, XIII, The national formulary, XVII, United States Pharmacopeial Conventions Inc, 1578-9.
[10] Ward HT, Kammer Mayer K. Sedimentation in the laboratory design data from laboratory experimentation. Ind Eng Chem 1940; 32:622-6.
- Abstract Viewed: 289 times
- IJPS_Volume 7_Issue 4_Pages 231-236 Downloaded: 175 times